HMG-CoA reductase inhibitor improves endothelial dysfunction in spontaneous hypertensive rats via Down-regulation of caveolin-1 and activation of endothelial nitric oxide synthase

Journal of Korean Medical Science

Volumn 25, Issue 1, 2010, Pages 16-23

  Suh, Jung Won ^a,b   Choi, Dong Ju ^a,b   Chang, Hyuk Jae ^a,b   Cho, Young Seok ^a,b   Youn, Tae Jin ^a,b   Chae, In Ho ^a,b   Kim, Kwang Il ^a,b   Kim, Cheol Ho ^a,b   Kim, Hyo soo ^a   Oh, Buyng Hee ^a   Park, Young Bae ^a  

^a Seoul National University   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

Author keywords

Caveolins; Hydroxymethylglutaryl CoA reductase inhibitors; Nitric oxide; Nitric oxide synthase type III

Indexed keywords

ACETYLCHOLINE; CAVEOLIN 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC OXIDE; PYRIMIDINE DERIVATIVE; ROSUVASTATIN; SULFONAMIDE;

ANIMAL; AORTA; ARTICLE; BLOOD; BLOOD PRESSURE; DOWN REGULATION; DRUG ADMINISTRATION; DRUG EFFECT; ENZYMOLOGY; HYPERTENSION; MALE; METABOLISM; PATHOPHYSIOLOGY; PHOSPHORYLATION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; VASCULAR ENDOTHELIUM; VASODILATATION;

ACETYLCHOLINE; ANIMALS; AORTA; BLOOD PRESSURE; CAVEOLIN 1; DOWN-REGULATION; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIUM, VASCULAR; FLUOROBENZENES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; PYRIMIDINES; RATS; RATS, INBRED SHR; SULFONAMIDES; VASODILATION;

EID: 77949317723     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2010.25.1.16     Document Type: Article

References (30)

1. Hermann M, Flammer A, Luscher TF. Nitric oxide in hypertension. J Clin Hypertens (Greenwich) 2006; 8 (12 Suppl 4): 17-29.
2. Spieker LE, Noll G, Ruschitzka FT, Maier W, Lüscher TF. Working under pressure: the vascular endothelium in arterial hypertension. J Hum Hypertens 2000; 14: 617-30.
3. Münzel T, Sinning C, Post F, Warnholtz A, Schulz E. Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. Ann Med 2008; 40: 180-96.
4. Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006; 113: 1708-14.
5. Fujiwara N, Osanai T, Kamada T, Katoh T, Takahashi K, Okumura K. Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension: modulation of nitric oxide synthesis by salt intake. Circulation 2000; 101: 856-61.
6. Klahr S. The role of nitric oxide in hypertension and renal disease progression. Nephrol Dial Transplant 2001; 16 (Suppl 1): 60-2.
7. Li H, Poulos TL. Structure-function studies on nitric oxide synthases. J Inorg Biochem 2005; 99: 293-305.
8. Searles CD. Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression. Am J Physiol Cell Physiol 2006; 291: C803-16.
9. Fulton D, Fontana J, Sowa G, Gratton JP, Lin M, Li KX, Michell B, Kemp BE, Rodman D, Sessa WC. Localization of endothelial nitric-oxide synthase phosphorylated on serine 1179 and nitric oxide in Golgi and plasma membrane defines the existence of two pools of active enzyme. J Biol Chem, 2002; 277: 4277-84.
10. Li H, Junk P, Huwiler A, Burkhardt C, Wallerath T, Pfeilschifter J, Förstermann U. Dual effect of ceramide on human endothelial cells: induction of oxidative stress and transcriptional upregulation of en endothelial nitric oxide synthase. Circulation 2002; 106: 2250-6.
11. Zalba G, Beaumont FJ, San José G, Fortuńo A, Fortuńo MA, Diez J. Is the balance between nitric oxide and superoxide altered in spontaneously hypertensive rats with endothelial dysfunction? Nephrol Dial Transplant 2001; 16 (Suppl 1): 2-5.
12. Rothberg KG, Heuser JE, Donzell WC, Ying YS, Glenney JR, Anderson RG. Caveolin, a protein component of caveolae membrane coats. Cell 1992; 68: 673-82.
13. Quest AF, Leyton L, Párraga M. Caveolins, caveolae and lipid rafts in cellular transport, signaling, and disease. Biochem Cell Biol 2004; 82: 129-44.
14. Mount PF, Kemp BE, Power DA. Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation. J Mol Cell Cardiol 2007; 42: 271-9.
15. Cohen AW, Hnasko R, Schubert W, Lisanti MP. Role of caveolae and caveolins in health and disease. Physiol Rev 2004; 84: 1341-79.
16. Grayson TH, Ohms SJ, Brackenbury TD, Meaney KR, Peng K, Pit-telkow YE, Wilson SR, Sandow SL, Hill CE. Vascular microarray profiling in two models of hypertension identifies caveolin-1, Rgs2 and Rgs5 as antihypertensive targets. BMC Genomics 2007; 8: 404.
17. Lahera V, Goicoechea M, de Vinuesa SG, Miana M, de las Heras N, Cachofeiro V, Luňo J. Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins. Curr Med Chem 2007; 14: 243-8.
18. Harris MB, Blackstone MA, Sood SG, Li C, Goolsby JM, Venema VJ, Kemp BE, Venema RC. Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Am J Physiol Heart Circ Physiol 2004; 287: H560-6.
19. Dilaveris P, Giannopoulos G, Riga M, Synetos A, Stefanadis C. Beneficial effects of statins on endothelial dysfunction and vascular stiffness. Curr Vasc Pharmacol 2007; 5: 227-37.
20. Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, Jackson G, Braunwald E PROVE IT-TIMI 22 Investigators. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. Am Coll Cardiol 2005; 46: 1405-10.
21. Wassmann S, Laufs U, Ba_umer AT, Mu_ller K, Ahlbory K, Linz W, Itter G, Rösen R, Böhm M, Nickenig G. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001; 37: 1450-7.
22. Zhou MS, Jaimes EA, Raij L. Atorvastatin prevents end-orgán injury in salt-sensitive hypertension: role of eNOS and oxidant stress. Hypertension 2004; 44: 186-90.
23. Bell RM, Yellon DM. Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of PI3K, Akt and eNOS. J Mol Cell Cardiol 2003; 35: 185-93.
24. Fulton D, Babbitt R, Zoellner S, Fontana J, Acevedo L, McCabe TJ, Iwakiri Y, Sessa WC. Targeting of endothelial nitric-oxide synthase to the cytoplasmic face of the Golgi complex or plasma membrane regulates Akt-versus calcium-dependent mechanisms for nitric oxide release. J Biol Chem 2004; 279: 30349-57.
25. Razani B, Engelman JA, Wang XB, Schubert W, Zhang XL, Marks CB, Macaluso F, Russell RG, Li M, Pestell RG, Di Vizio D, Hou H Jr, Kneitz B, Lagaud G, Christ GJ, Edelmann W, Lisanti MP. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem 2001; 276: 38121-38.
26. Vera R, Saánchez M, Galisteo M, Villar IC, Jimenez R, Zarzuelo A, Peárez-Vizcaińo F, Duarte J. Chronic administration of genistein improves endothelial dysfunction in spontaneous hypertensive rats: involvement of eNOS, caveolin and calmodulin expression and NADPH oxidase activity. Clin Sci (Lond) 2007; 112: 183-91.
27. Pelat M, Dessy C, Massion P, Desager JP, Feron O, Balligand JL. Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-/mice in vivo. Circulation 2003; 107: 2480-6.
28. Laufs U, Wassmann S, Hilgers S, Ribaudo N, Bo_hm M, Nickenig G. Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol 2001; 88: 1306-7.
29. Susic D, Varagic J, Ahn J, Slama M, Frohlich ED. Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models. J Am Coll Cardiol 2003; 42: 1091-7.
30. Zhou MS. Upregulation of nitric oxide, inhibition of oxidative stress, and antihypertensive effects of statins. Hypertension 2007; 49: e43.